FGFR2 and infantile convulsions and choreoathetosis: In addition, FGFR2 fusion genes with frequencies of up to 45% in iCCA,28, 29, 34, 35 constitute new targets for therapy36 and can be regarded as a breakthrough for iCCA patient management.